Clinical Research

Institut Gustave Roussy

Address
114 Rue Edouard Vaillant

Sponsor Overview

assignment
50
sponsored trials
science
85
molecules
location_city
414
research centres
public
18
countries
person_search
860
investigators

Specializations

Thoracic Oncology and Advanced Solid Tumours

Research activity includes non-small cell lung cancer, small-cell lung cancer, and other poorly differentiated neuroendocrine carcinomas, with additional interest in pancreatic ductal adenocarcinoma, oligometastatic disease, and biomarker-defined tumour subsets.

  • NSCLC
  • SCLC and neuroendocrine carcinomas
  • Pancreatic cancer
  • Oligometastatic solid tumours

Work in this area also extends to metastatic renal cell carcinoma and KRAS G12C-mutated lung cancer, reflecting a strong focus on targeted and immunologic treatment strategies.

Breast Cancer and Hormone-Receptor–Driven Disease

The sponsor funds studies across early-stage breast cancer, triple-negative breast cancer, HER2-positive and HER2-low disease, as well as advanced hormone-receptor positive breast cancer and treatment-related symptom control.

  • Triple-negative breast cancer
  • HER2-positive and HER2-low breast cancer
  • Hormone-receptor positive advanced breast cancer
  • Adjuvant endocrine therapy-related pain

Its portfolio also includes window-of-opportunity and neoadjuvant investigations in breast cancer, with attention to immune response and molecularly selected subgroups.

Gastrointestinal, Hepatobiliary, and Pelvic Malignancies

Clinical research spans rectal adenocarcinoma, colorectal cancer, hepatocellular carcinoma, cervical cancer, and HPV-related squamous intraepithelial lesions, with a recurring interest in organ preservation and local control.

  • Rectal cancer
  • Hepatocellular carcinoma
  • Cervical and anal HPV-related disease
  • Metastatic colorectal cancer

Additional activity covers mucosal melanoma and head and neck squamous cell carcinoma, including postoperative and radiotherapy-linked treatment settings.

Haematological Malignancies and Pediatric Oncology

Funding supports studies in acute myeloid leukemia, relapsed/refractory ALK-positive anaplastic large cell lymphoma, high-risk neuroblastoma, diffuse intrinsic pontine glioma, and other pediatric and adolescent cancers.

  • Acute myeloid leukemia
  • ALK-positive anaplastic large cell lymphoma
  • High-risk neuroblastoma
  • Diffuse midline glioma

The portfolio also includes germ-cell tumours and molecularly enriched paediatric solid tumours, with emphasis on refractory and high-risk disease.

Rare Tumours, Genomic Subtypes, and Immunotherapy

Research extends to sarcoma, mucosal melanoma, renal carcinoma, endometrial cancer, and other molecularly selected solid tumours defined by DNA repair deficiency, chromatin remodelling alterations, or tertiary lymphoid structures.

  • Soft tissue sarcoma
  • Endometrial cancer
  • DNA repair-deficient tumours
  • Immune checkpoint–based therapy

Across these programmes, the sponsor is active in biomarker-driven oncology, radiotherapy combinations, and personalised treatment for uncommon and difficult-to-treat malignancies.

Sponsored Trials

Trial Name Country Status
Adjuvant Pembrolizumab and Paclitaxel Versus Surveillance in Early Triple-Negative Breast Cancer with High Stromal Tumor-Infiltrating LymphocytesFrance FranceSpain SpainRecruiting
Adjuvant Phase III Randomized Trial of Capecitabine plus Temozolomide Versus Surveillance in R0‑resected Stage I‑III Pancreatic Neuroendocrine Tumors (ADJUPANET)France FranceNot Yet Recruiting
An open label phase II platform modular study exploring the efficacy and safety of the Valemetostat (EZH1/2 inhibitor) in patients with selected solid tumors (EZHiSWITCH)France FranceRecruiting
Comparison of Seven-Day versus Continuous Venetoclax Exposure with Azacitidine in Treatment-Naïve Patients with Ineligible-for-Intensive Acute Myeloid LeukemiaFrance FranceSpain SpainRecruiting
Efficacy and Safety of Cannabidiol Oral Solution for Aromatase Inhibitor-Induced Musculoskeletal Pain in Early Hormone-Receptor Positive Breast CancerFrance FranceNot Yet Recruiting
Efficacy and Safety of Cannabidiol Oral Solution for Aromatase Inhibitor-Related Joint Pain in Early Hormone-Receptor Positive Breast CancerFrance FranceNot Yet Recruiting
Efficacy Comparison of Nivolumab-Ipilimumab Versus Immune Checkpoint Inhibitor-VEGFR TKI Combinations in Untreated Metastatic Renal Cell CarcinomaAustria AustriaBelgium BelgiumCzechia CzechiaDenmark DenmarkFinland FinlandFrance FranceGermany GermanyGreece GreeceItaly ItalyThe Netherlands The NetherlandsRecruiting
Efficacy of ONC201 and Everolimus with Radiotherapy in Newly Diagnosed Diffuse Midline Gliomas H3K28M Mutant or EZHIP Positive PatientsDenmark DenmarkFinland FinlandFrance FranceGreece GreeceNorway NorwaySpain SpainSweden SwedenRecruiting
Efficacy of PD-L1 and TIGIT Targeting in TLS-Positive Advanced or Metastatic NSCLC in Systemically Naïve or Chemotherapy and PD1/PDL1 Antagonist-Treated AdultsFrance FranceNot Recruiting
Efficacy of Tislelizumab Versus Placebo in Patients with Molecular Residual Disease Post-Curative Therapy: A Randomized Controlled TrialFrance FranceRecruiting
1–10 of 50
1 / 5

Data & Insights

science
Molecule Portfolio
Compounds under investigation
2
Exclusive Molecules
out of 85 total (2% not shared with other sponsors)

This sponsor works with 85 molecules, of which 2 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
33%
Return partnership rate
135 of 414 sites collaborated multiple times

This sponsor has worked with 414 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Neoplasms36 trials
    853 other sponsors
  • 2.
    Respiratory Tract Diseases6 trials
    277 other sponsors
  • 3.
    Not possible to specify5 trials
    220 other sponsors
  • 4.
    Digestive System Diseases4 trials
    280 other sponsors
  • 5.
    Immune System Diseases4 trials
    322 other sponsors
  • 6.
    Male Urogenital Diseases3 trials
    111 other sponsors
  • 7.
    Pathological Conditions, Signs and Symptoms2 trials
    91 other sponsors
  • 8.
    Skin and Connective Tissue Diseases2 trials
    247 other sponsors
  • 9.
    Hemic and Lymphatic Diseases1 trial
    249 other sponsors
  • 10.
    Hormonal diseases1 trial
    89 other sponsors
  • 11.
    Investigative Techniques1 trial
    35 other sponsors
  • 12.
    Musculoskeletal Diseases1 trial
    238 other sponsors
  • 13.
    Otorhinolaryngologic Diseases1 trial
    49 other sponsors
  • 14.
    Therapeutics1 trial
    87 other sponsors

Partnered Research Centres

414 centres
location_city
assignment352
Aarhus University Hospital
Address
Palle Juul-Jensens Boulevard 99, 8200 Aarhus
Learn morearrow_forward
location_city
assignment57
Aix Marseille University
Address
264 Boulevard de Saint Pierre, 13005 Marseille
Learn morearrow_forward
location_city
assignment247
Alexandra Hospital
Address
Vassilissis Sofias Avenue 80, 115 28 Athens
Learn morearrow_forward
location_city
assignment283
Algemeen Ziekenhuis Delta
Address
Deltalaan 1, 8800 Roeselare
Learn morearrow_forward
location_city
assignment47
ARNAS Civico Di Cristina Benfratelli
Address
Piazza Nicola Leotta 4, 90127 Palermo
Learn morearrow_forward
location_city
assignment57
ARNAS G. Brotzu
Address
Piazzale Alessandro Ricchi 1, 09121 Cagliari
Learn morearrow_forward
Page 1 of 69

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Institut Gustave Roussy.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.